Kwarlay.com

Navigating the News Maze with Clarity

Medicine

FDA Approves Axsome Therapeutics’ Symbravo for Migraine with or without Aura

Clinical trials demonstrated that a single dose of Symbravo provides rapid migraine relief, sustains efficacy for up to 48 hours, and reduces the need for rescue medication.

LEAVE A RESPONSE

Your email address will not be published. Required fields are marked *